Recursion Pharmaceuticals, Inc. (RXRX) stock
RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/302% below fair value
$2.90−0.28 (-8.79%)
Close on Nov 16, 2026Market cap $1.56BP/E –Yield –
Recursion Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Recursion Pharmaceuticals's ebitda for the twelve months ending Jun 30, 2026 was -$465.65M. For fiscal 2025 it was -$564.43M. The highest annual figure on record is -$59.95M in fiscal 2019.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$564.43M | – |
| FY2024 | Dec 31, 2024 | -$442.51M | – |
| FY2023 | Dec 31, 2023 | -$325.66M | – |
| FY2022 | Dec 31, 2022 | -$233.97M | – |
| FY2021 | Dec 31, 2021 | -$174.37M | – |
| FY2020 | Dec 31, 2020 | -$80.67M | – |
| FY2019 | Dec 31, 2019 | -$59.95M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$116.80M | – |
| Q1 FY2026 | Mar 31, 2026 | -$108.83M | – |
| Q4 FY2025 | Dec 31, 2025 | -$88.86M | – |
| Q3 FY2025 | Sep 30, 2025 | -$151.16M | – |
| Q2 FY2025 | Jun 30, 2025 | -$152.38M | – |
| Q1 FY2025 | Mar 31, 2025 | -$172.04M | – |
| Q4 FY2024 | Dec 31, 2024 | -$170.82M | – |
| Q3 FY2024 | Sep 30, 2024 | -$91.16M | – |
| Q2 FY2024 | Jun 30, 2024 | -$91.58M | – |
| Q1 FY2024 | Mar 31, 2024 | -$88.96M | – |
| Q4 FY2023 | Dec 31, 2023 | -$91.38M | – |
| Q3 FY2023 | Sep 30, 2023 | -$91.97M | – |
| Q2 FY2023 | Jun 30, 2023 | -$76.17M | – |
| Q1 FY2023 | Mar 31, 2023 | -$66.14M | – |
| Q4 FY2022 | Dec 31, 2022 | -$57.77M | – |
| Q3 FY2022 | Sep 30, 2022 | -$59.58M | – |
| Q2 FY2022 | Jun 30, 2022 | -$63.41M | – |
| Q1 FY2022 | Mar 31, 2022 | -$53.21M | – |
| Q4 FY2021 | Dec 31, 2021 | -$62.72M | – |
| Q3 FY2021 | Sep 30, 2021 | -$43.97M | – |
| Q2 FY2021 | Jun 30, 2021 | -$38.60M | – |
| Q1 FY2021 | Mar 31, 2021 | -$29.08M | – |
| Q4 FY2020 | Dec 31, 2020 | -$24.46M | – |
| Q3 FY2020 | Sep 30, 2020 | -$21.62M | – |
| Q2 FY2020 | Jun 30, 2020 | -$17.19M | – |
| Q1 FY2020 | Mar 31, 2020 | -$17.41M | – |
See a number that looks wrong?